| UPC n = 67 | LAPC n = 53 | MPC n = 14 |
---|---|---|---|
Chemotherapy regimens | |||
 based on mFFX | 60 (90) | 47 (89) | 13 (93) |
 GnP | 4 (6) | 3 (6) | 1 (7) |
 Sequential use of GnP and mFFX | 3 (4) | 3 (6) | 0 (0) |
 Duration of systemic treatment (months) | 4.53 (1.83–14.47) | 4.17 (1.83–12.03) | 6.52 (2.33–14.47) |
Treatment response | |||
 PR | 35 (52) | 24 (45) | 11 (79) |
 SD | 32 (48) | 29 (55) | 3 (21) |
Change in levels of preoperative tumor markers | |||
 Decrease to normal | 24 (36) | 17 (32) | 7 (50) |
 Decrease > 50% without normalization | 22 (33) | 18 (34) | 4 (29) |
 Decrease < 50% or stable | 13 (19) | 11 (21) | 2 (14) |
 Negative before treatment | 8 (12) | 7 (13) | 1 (7) |
Adverse events (grade) | |||
 0 | 6 (9) | 2 (4) | 4 (29) |
 1 | 10 (15) | 8 (15) | 2 (14) |
 2 | 17 (25) | 16 (30) | 1 (7) |
 3 | 29 (43) | 24 (45) | 5 (36) |
 4 | 5 (7) | 3 (6) | 2 (14) |
Severe adverse events | |||
 Neutropenia | 23(34) | 18(34) | 5(36) |
 Anemia | 11(16) | 7(13) | 4(29) |
 Thrombocytopenia | 8(12) | 5(9) | 3(21) |
 Febrile neutropenia | 3(4) | 3(6) | 0(0) |
 Fatigue | 2(3) | 2(4) | 0(0) |